PWC
GLMD icon

PYA Waltman Capital’s Galmed Pharmaceuticals GLMD Stock Holding History

PYA Waltman Capital’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6
Closed – – 105
2022
Q3 		$0 Hold
6
– – ﹤0.01% 200
2022
Q2 		$1K Hold
6
– – ﹤0.01% 196
2022
Q1 		$2K Hold
6
– – ﹤0.01% 182
2021
Q4 		$2K Buy
+6
New +$2.71K ﹤0.01% 180

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PYA Waltman Capital's GLMD Position: Q4 2022 in Review

PYA Waltman Capital sold out of Galmed Pharmaceuticals (GLMD) in Q4 2022, closing a stake of 6 shares.

PYA Waltman Capital first reported a position in GLMD in Q4 2021 and held it in 4 quarters. The position peaked at $2K in Q1 2022. 22 funds tracked by Wall St. Rank hold GLMD as of Q4 2022.

  • PYA Waltman Capital reported no remaining Galmed Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • PYA Waltman Capital sold 6 Galmed Pharmaceuticals shares in Q4 2022.
  • PYA Waltman Capital first reported a position in Galmed Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • PYA Waltman Capital's Galmed Pharmaceuticals position peaked at $2K in Q1 2022.
  • 22 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2022.

Based on PYA Waltman Capital's 13F filing for Q4 2022, filed 14 Feb 2023.